Binod Dhakal, MD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Clinical Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Nepali, Hindi

Clinical Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Binod Dhakal, MD, MS, is Assistant Professor of Medicine, at the Medical College of Wisconsin, Division of Hematology, specializing in multiple myeloma and plasma cell disorders. He graduated from Manipal College of Medical Sciences, Pokhara Nepal in 2004, completed Internal Medicine Residency at Saint Francis Hospital Evanston Illinois, and a fellowship in hematology/oncology at the Medical College of Wisconsin, where he also served as a Chief Fellow. Prior to joining the fellowship, he was Assistant Professor of Medicine at the Medical College in Wisconsin in the Division of General Internal Medicine. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. He has also won several awards during his fellowship which include the American Society of Clinical Oncology (ASCO) Merit Award; Medical College of Wisconsin Affiliated Hospitals (MCWAH) research award; Central Society for Clinical and Translational Research (CSCTR) best oral abstract and travel trainee award; American Society for Blood and Marrow Transplantation (ASBMT) clinical research training course; and, Outstanding Medical School Teacher award. Additionally, he was the recipient of the Mazie Froedtert Willms and Sue Froedtert Cancer Scholarship, and obtained his Master’s Degree in Clinical and Translational Science.

Research Interests

Dr. Dhakal's current research interests focus on novel drug treatments for patients with multiple myeloma and related plasma cell disorders by designing and conducting early phase clinical trials.

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.

(Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM.) J Clin Oncol. 2025 Jun 03:JCO2500760 PMID: 40459151 06/03/2025
Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data.

(Biran N, Dhakal B, Niesvizky R, Lentzsch S, Bhutani D, McKay JT, Vesole DH, Nooka A, Paul B, Hari PN, D'Ambrosi S, Kuiper R, van Vliet M, Siegel D, Usmani SZ, van Rhee F.) Br J Haematol. 2025 Jun;206(6):1642-1653 PMID: 40231946 SCOPUS ID: 2-s2.0-105002595395 04/15/2025
Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database.

(Dhakal B, He J, Schecter JM, Deraedt W, Slaughter A, Lonardi C, Nair S, He J, Lee S, Cost P, Patel N, Koneru M, Einsele H.) Clin Lymphoma Myeloma Leuk. 2025 Jun;25(6):e394-e403 PMID: 39966019 SCOPUS ID: 2-s2.0-85217889094 02/19/2025
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.

(Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Bhurtel E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar A, Liu Y, Locke F, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD Jr, Cowan AJ, Kaur G.) Blood Adv. 2025 May 13;9(9):2336-2340 PMID: 40088469 PMCID: PMC12127628 SCOPUS ID: 2-s2.0-105005798542 03/16/2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.

(Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S, US Multiple Myeloma Immunotherapy Consortium.) J Clin Oncol. 2025 May;43(13):1597-1609 PMID: 39965175 PMCID: PMC12037312 SCOPUS ID: 2-s2.0-85218769357 02/18/2025
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma.

(Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, Balev M, Bhutani D, Shrestha A, Thanendrarajan S, Dhakal B, Zangari M, Trikannad A, Vellanki S, Al-Hadidi S, Lentzsch S, van Rhee F, Bag A, D'Souza A, Shah N, Chakraborty R, Shah MR, Schinke C.) Blood Cancer J. 2025 Apr 23;15(1):74 PMID: 40268898 PMCID: PMC12018942 SCOPUS ID: 2-s2.0-105003139880 04/24/2025
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy.

(Bal S, Magnusson T, Ravi G, Giri S, Godby K, Dhakal B, Callander NS, Silbermann RW, Dholaria B, Reddy VB, Costa LJ.) Blood Cancer J. 2025 Apr 23;15(1):73 PMID: 40268941 PMCID: PMC12019237 SCOPUS ID: 2-s2.0-105003126302 04/24/2025
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.

(Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Maringanti SA, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S, US Multiple Myeloma Immunotherapy Consortium.) J Clin Oncol. 2025 Apr 10;43(11):1399 PMID: 40053892 03/07/2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

(Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen DK, Ferreri CJ, Freeman CL, Afrough A, Anderson LD Jr, Dhakal B, Dhanda DS, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patwardhan P, Qazilbash MH, Usmani SZ, Patel KK, Nishihori T, Ganguly S, Pasquini MC.) Blood. 2025 Apr 08 PMID: 40198886 SCOPUS ID: 2-s2.0-105004741731 04/09/2025
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma.

(Giri S, Dhakal B, Callander NS, Medvedova E, Godby K, Dholaria B, Bal S, Ravi G, Chhabra S, Silbermann R, Costa LJ.) Blood. 2025 Apr 07 PMID: 40193714 SCOPUS ID: 2-s2.0-105006948795 04/07/2025
Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable.

(Alsina M, Dhakal B, Pantin J, Huff CA, Janakiram M.) Future Oncol. 2025 Apr;21(10):1137-1144 PMID: 40098471 PMCID: PMC11988239 SCOPUS ID: 2-s2.0-105000821564 03/18/2025
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma.

(Chari A, Bal S, Ailawadhi S, Krishnan A, Patel KK, Berdeja JG, Garfall A, Callander N, Banerjee R, Alsina M, Nooka AK, Dhakal B, Gasparetto C, Costello C.) Clin Lymphoma Myeloma Leuk. 2025 Mar 11 PMID: 40175263 04/03/2025